Status:
COMPLETED
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Lead Sponsor:
AbbVie
Conditions:
Psoriasis
Psoriatic Arthritis
Eligibility:
All Genders
19+ years
Brief Summary
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. Psoriatic arthritis (PsA) is a type of arthritis (swelling and stif...
Eligibility Criteria
Inclusion
- Suitable for the treatment with risankizumab according to the approved local label.
- Voluntarily agree to participate in this study and sign informed consent.
Exclusion
- \- Contraindications to risankizumab as listed on the approved local label.
Key Trial Info
Start Date :
August 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 13 2025
Estimated Enrollment :
2324 Patients enrolled
Trial Details
Trial ID
NCT04433442
Start Date
August 4 2020
End Date
June 13 2025
Last Update
August 17 2025
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Inje University - Busan Paik Hospital /ID# 238911
Busan, Busan Gwang Yeogsi, South Korea, 47392
2
Inje University Haeundae Hospital /ID# 238933
Busan, Busan Gwang Yeogsi, South Korea, 48108
3
Pusan National University Hospital /ID# 238896
Busan, Busan Gwang Yeogsi, South Korea, 49241
4
Dankook University Hospital /ID# 223995
Cheonan-si, Chungcheongnam-do, South Korea, 31116